Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook

Novo Nordisk (NVO) shares plunged 20% after the company sharply reduced its full-year sales growth guidance from 13%-21% to 8%-14%. This downgrade was primarily attributed by outgoing CEO Lars Jørgensen to the unexpected and sustained prevalence of compounded GLP-1 products in the U.S. market, which continues to impact sales volumes despite the official end of drug shortages. The company acknowledges this has led to market share erosion, with incoming CEO Mike Doustdar emphasizing the need to regain growth.

Analysis

Novo Nordisk's (NVO) stock plunged 20% following a substantial downward revision of its full-year sales growth guidance from 13%-21% to 8%-14%, a significant deceleration from the 26% growth achieved in 2024. Management explicitly attributes this downgrade to the unexpected persistence of the U.S. compounded, or copycat, GLP-1 drug market, which continues to serve approximately one million patients. This situation reveals a critical miscalculation in the company's previous forecast, which had assumed this gray market would contract after the FDA declared an end to the official drug shortage. The issue has led to tangible market share erosion and a strategic fallout, evidenced by Novo's termination of its sales partnership with Hims & Hers (HIMS) over its continued sale of compounded products. In contrast, competitor Eli Lilly (LLY) is portrayed as taking a more aggressive stance by lobbying Congress for stricter enforcement, potentially positioning it more defensively. The leadership transition adds another layer of uncertainty, with the incoming CEO acknowledging the setback and framing his mandate around reclaiming the company's growth path and market share.

Key Decisions for Investors

• Investors should recalibrate near-term growth expectations for Novo Nordisk, as the significant guidance cut and acknowledged market share loss to compounded drugs introduce substantial execution risk.
• Consider the divergent strategies between Novo Nordisk and Eli Lilly, as Lilly's more aggressive lobbying against compounded products may offer it a competitive advantage in defending its market share from this specific headwind.
• Closely monitor future FDA enforcement actions and potential legislative changes targeting compounded drugs, as stricter regulation is the primary catalyst cited by management as necessary for Novo Nordisk to regain its projected growth trajectory.